{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-008625","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.904965+00:00","generated_at":"2026-06-17T09:15:18.867042+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pulse Biosciences reports Q4 2022 net loss of $9.2M, no revenue; shifts focus to atrial fibrillation","bullets":["Q4 2022 GAAP net loss of $9.2M vs $15.4M in Q4 2021; non-GAAP net loss $8.1M.","No revenue in Q4 2022; full-year 2022 revenue $0.7M from discontinued dermatology.","Cash, cash equivalents and investments $61.1M at Dec 31, 2022; cash burn reduced to $8.0M in Q4.","Company focuses on nsPFA cardiac ablation for atrial fibrillation; FDA pre-submission for clamp planned in Q2 2023.","Appointed Manmeet S. Soni as Lead Independent Director with $80,000 annual fee."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-008625","json":"https://secwatch.observer/filing/0001437749-23-008625.json","markdown":"https://secwatch.observer/filing/0001437749-23-008625.md","text":"https://secwatch.observer/filing/0001437749-23-008625.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000143774923008625/0001437749-23-008625-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000143774923008625/plse20230329_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T09:15:18.867042+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ec428fcf4e4597b60507b40c470a91771d44a4cb","claim":"PULSE BIOSCIENCES, INC. reported financial results for the fourth quarter and full year ended December 31, 2022.","evidence_excerpt":"Pulse Biosciences, Inc. (the “Company”) announced its financial and operational results for the fiscal quarter and full year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1625101/000143774923008625/0001437749-23-008625-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"97a47e7646","claim":"Manmeet S. Soni was appointed as Lead Independent Director at PULSE BIOSCIENCES, INC..","evidence_excerpt":"On March 28, 2023, the Company's Board of Directors appointed Manmeet S. Soni to the newly created position of Lead Independent Director of the Board of Directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1625101/000143774923008625/0001437749-23-008625-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Lead Independent Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}